Search MalaCards:
MCID: PRS041

Prostate Carcinoma malady
4 drugs, 558 genes, 15 tissues, 1835 related diseases, 29 phenotypes, 949 articles, clinical trials, genetic tests.

Summaries for Prostate Carcinoma

about this section
Sources:
23MedlinePlus, 2CDC, 44Wikipedia, 33OMIM, 22MalaCards
See all sources

Export this MalaCard
MedlinePlus: The prostate is the gland below a man's bladder that produces fluid for semen. prostate cancer is common among older men. it is rare in men younger than 40. risk factors for developing prostate cancer include being over 65 years of age, family history, being african-american, and some genetic changes. symptoms of prostate cancer may include problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling low back pain pain with ejaculation your doctor will diagnose prostate cancer by feeling the prostate through the wall of the rectum or doing a blood test for prostate-specific antigen (psa). other tests include ultrasound, x-rays, or a biopsy. treatment often depends on the stage of the cancer. how fast the cancer grows and how different it is from surrounding tissue helps determine the stage. men with prostate cancer have many treatment options. the treatment that's best for one man may not be best for another. the options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. you may have a combination of treatments. nih: national cancer institute23

MalaCards: Prostate Carcinoma, also known as prostate cancer, is related to prostatitis and carcinoma. An important gene associated with Prostate Carcinoma is KLK3 (kallikrein-related peptidase 3), and among its related pathways are Pathways in cancer and Focal adhesion. The drugs carmustine and diethylstilbestrol diphosphate and the compounds atp and progesterone have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, lymph node and skeletal muscle, and related mouse phenotypes are growth/size and cellular.

CDC: Prostate cancer is the most common cancer in men. In the United States in 2008,* 214,633 men were diagnosed with prostate cancer, and 28,471 men died from it.† CDC provides men, doctors, and policymakers with the latest information about prostate cancer.2

Wikipedia: Prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive...44 more...

OMIM: 176807

Aliases & Descriptions for Prostate Carcinoma

about this section
Sources:
2CDC, 43UMLS, 7diseasecard, 8DISEASES, 33OMIM, 32Novoseek , 23MedlinePlus, 6Disease Ontology, 16GeneTests, 27NCIt, 40SNOMED-CT
See all sources

Aliases & Descriptions:

prostate carcinoma 6 8 32 43
prostate cancer 7 8 33 32 23
carcinoma of prostate 6 16
cancer of prostate 6 16
carcinoma of prostate (disorder) 6
malignant neoplasm of prostate 43
malignant neoplasms 43
carcinoma 43

External Ids:

NCIt27 C4863

Related Diseases for Prostate Carcinoma

about this section
Sources:
13GeneCards, 14GeneDecks
See all sources

Diseases related to prostate carcinoma by text searches and GeneDecks gene sharing:

(show top 50)    (show all 1832)
idRelated DiseaseScoreTop Affiliating Genes
1prostatitis87.4ZNF79, PIAS3, PIK3R1, PIK3CG, PIM1, LRP1
2carcinoma87.2ZNF79, PIAS3, PIK3R1, PIK3CG, PIM1, LRP1
3lung carcinoma64.4PIK3R1, PIK3CG, KLF6, RECK, PCNA, BTG2
4hepatitis62.4PIAS3, PIK3R1, PIK3CG, PIM1, LRP1, KLF6
5melanoma62.2PIK3R1, PIK3CG, PIM1, LRP1, KLF6, RECK
6adenocarcinoma62.2PIK3R1, PIK3CG, PIM1, LRP1, KLF6, RECK
7leukemia61.0PIK3R1, PIK3CG, PIM1, LRP1, KLF6, RECK
8neuronitis60.7PIK3R1, PIK3CG, PIM1, LRP1, KLF6, RECK
9esophagitis59.7PIK3CG, PIM1, KLF6, RECK, RELA, CNR1
10ovarian carcinoma59.7PIK3CG, RECK, RELA, VTN, PCNA, RB1
11pancreatitis59.5PIK3R1, PIK3CG, PIM1, LRP1, KLF6, RECK
12cervicitis59.4PIK3CG, RECK, RELA, CNR1, VTN, PCNA
13colon carcinoma57.5PIK3R1, PIK3CG, CNR1, VTN, SELP, SETD2
14adenoma55.4RECK, CNR1, PCNA, RB1, SETD2, SERPINB5
15breast carcinoma55.1PIK3R1, PIK3CG, LRP1, RECK, VTN, PCNA
16gastric cancer55.0PIK3R1, PIK3CG, PIM1, KLF6, RECK, RELA
17colon cancer54.0PIK3R1, PIK3CG, KLF6, RECK, RELA, CNR1
18endometrial carcinoma53.9PIK3CG, LRP1, RELA, PCNA, RB1, SERPINB5
19oral squamous cell carcinoma53.9PIM1, RECK, VTN, PCNA, RB1, RBL2
20renal cell carcinoma53.8RELA, PCNA, SELP, SETD2, VIM, BRAF
21hepatocellular carcinoma52.5PIK3R1, PIK3CG, KLF6, RECK, RELA, SGCE
22thyroiditis51.8ZNF79, PIK3R1, PIK3CG, LRP1, NCOA4, RECK
23esophageal squamous cell carcinoma51.7PIM1, RECK, RELA, PCNA, RB1, SETD2
24prostate cancer, progression of50.7PIK3R1, KLF6, RECK, VTN, PCNA, RB1
25sarcoma50.4PIK3R1, PIK3CG, RECK, RELA, VTN, PCNA
26cervical carcinoma50.1PIK3CG, RECK, RELA, CNR1, VTN, PCNA
27neuroblastoma49.9PIK3R1, PIK3CG, LRP1, KLF6, RECK, RELA
28thyroid carcinoma49.7PIK3CG, PCNA, RB1, SERPINE1, VIM, BRAF
29nasopharyngitis48.9PIK3CG, KLF6, RECK, RELA, PCNA, RB1
30bladder carcinoma48.8PIK3CG, PCNA, RB1, RBL2, SERPINB5, VIM
31hypoxia48.5PIK3R1, PIK3CG, PIM1, LRP1, RECK, RELA
32pancreatic carcinoma47.9VTN, PCNA, RB1, SETD2, SERPINB5, VIM
33laryngitis47.8PIM1, RELA, PCNA, BTG2, RB1, SETD2
34non-small cell lung carcinoma47.8PCNA, RB1, SETD2, BRAF, VEGFA, VEGFC
35laryngeal squamous cell carcinoma47.2PIM1, PCNA, RB1, VEGFA, VEGFC, MYC
36cervical cancer47.2PIK3CG, RELA, VTN, PCNA, RB1, RBL2
37hepatitis b46.8PIK3R1, PIK3CG, PIM1, KLF6, RELA, VTN
38squamous cell carcinoma of the head and neck46.6PIK3CG, RELA, VTN, PCNA, BRAF, VEGFA
39squamous cell carcinoma46.3LGALS1, LGALS3, LGALS8, CD44, CDH1, MMP7
40endometrial cancer45.5PIK3R1, PIK3CG, PCNA, RB1, RBL2, RBL1
41osteosarcoma44.9PIK3CG, RECK, RELA, CNR1, VTN, PCNA
42lung adenocarcinoma44.4PIK3CG, LRP1, KLF6, PCNA, RB1, RBL2
43fibrosis44.3PIAS3, PIK3CG, LRP1, KLF6, RECK, RELA
44esophageal carcinoma44.1PCNA, RB1, RBL2, SERPINB5, VEGFA, VEGFC
45cholangiocarcinoma43.6PIK3CG, RECK, PCNA, RB1, RBL1, SERPINB5
46retinoblastoma43.5PIK3R1, PIK3CG, KLF6, RECK, PCNA, RB1
47small cell carcinoma42.8KLF6, PCNA, RB1, VIM, BRCA1, VEGFA
48myeloid leukemia42.3PIK3R1, PIK3CG, PIM1, KLF6, RECK, RELA
49ductal carcinoma in situ42.1PCNA, RB1, SERPINE1, VIM, BRCA1, VEGFA
50arthritis42.0PIK3CG, LRP1, RECK, RELA, CNR1, VTN

Graphical network of the top 20 diseases related to prostate carcinoma:



Graphical network of diseases related to prostate carcinoma

Clinical Features for Prostate Carcinoma

about this section
Sources:
33OMIM
See all sources
Clinical features from OMIM: 176807

Drugs & Therapeutics for Prostate Carcinoma

about this section
Sources:
4CenterWatch, 29NIH Clinical Center, 5ClinicalTrials, 43UMLS, 28NDF-RT
See all sources

Approved drugs:

Search CenterWatch for prostate carcinoma

Drug clinical trials:

Search ClinicalTrials for prostate carcinoma

Search NIH Clinical Center for prostate carcinoma

Search CenterWatch for prostate carcinoma

Inferred drug relations via UMLS/NDF-RT:

43 28 carmustine, diethylstilbestrol, diethylstilbestrol diphosphate, nilutamide

Genetic Tests for Prostate Carcinoma

about this section
Sources:
16GeneTests
See all sources

Genetic tests related to prostate carcinoma:

id Genetic test Affiliating Genes
1 Prostate Carcinoma
clinical/research 		BRCA2, CHEK2, CDS1, HSD3B2, HSD17B3, SRD5A2, RNASEL, ELAC2

Anatomical Context for Prostate Carcinoma

about this section
Sources:
22MalaCards
See all sources

MalaCards organs/tissues related to prostate carcinoma:

22
Bone marrow, Lymph node, Skeletal muscle, Small intestine, Colon, Liver, Lung, Thyroid, Breast, Prostate, Testis, T cells, B cells, Endothelial, Testis germ

Phenotypes for genes affiliated with Prostate Carcinoma

about this section
Sources:
25MGI
See all sources

MGI Mouse Phenotypes related to prostate carcinoma:

25 (show all 29)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1growth/size phenotypeMP:000537824.3PIK3R1, PIK3CG, PIM1, LRP1, KLF6, RECK
2cellular phenotypeMP:000538424.3PIK3R1, PIK3CG, PIM1, KLF6, RELA, SGCE
3homeostasis/metabolism phenotypeMP:000537623.2PIK3R1, PIK3CG, LRP1, RELA, CNR1, VTN
4mortality/agingMP:001076822.5LRP1, KLF6, RECK, RELA, CNR1, GCLC
5nervous system phenotypeMP:000363119.4LRP1, RECK, RELA, CNR1, BTG2, RB1
6cardiovascular system phenotypeMP:000538519.1PIK3R1, PIK3CG, LRP1, KLF6, RECK, RELA
7integument phenotypeMP:001077118.8PIK3CG, KLF6, RECK, RELA, CNR1, RB1
8hematopoietic system phenotypeMP:000539718.4PIM1, KLF6, PCNA, RBL1, BRAF, BRCA1
9immune system phenotypeMP:000538717.9LRP1, SGCE, RBL1, SELP, VIM, BRAF
10embryogenesis phenotypeMP:000538017.3KLF6, RECK, GCLC, RBL2, RBL1, SETD2
11behavior/neurological phenotypeMP:000538617.3LRP1, SGCE, CNR1, RB1, RBL1, SELP
12digestive/alimentary phenotypeMP:000538117.2RB1, RBL1, SERPINF1, BRAF, BRCA1, VEGFA
13skeleton phenotypeMP:000539017.1PIK3CG, LRP1, RECK, RELA, CNR1, BTG2
14normal phenotypeMP:000287316.6PIK3R1, LRP1, RELA, VTN, GCLC, RBL2
15reproductive system phenotypeMP:000538916.3KLF6, RBL2, RBL1, SERPINF1, NAB2, BRCA1
16muscle phenotypeMP:000536916.1PIK3R1, PIK3CG, LRP1, RELA, SGCE, RB1
17tumorigenesisMP:000200615.7PIK3R1, RB1, RBL2, RBL1, SERPINE1, BRAF
18vision/eye phenotypeMP:000539115.2RELA, RB1, RBL2, RBL1, SELP, SERPINF1
19limbs/digits/tail phenotypeMP:000537114.6RECK, RELA, RB1, RBL2, RBL1, BRCA1
20renal/urinary system phenotypeMP:000536714.3SELP, BRAF, BRCA1, BMP4, RARA, BCL2
21hearing/vestibular/ear phenotypeMP:000537713.5RB1, VDR, MYC, MYO6, BMP2, BMP4
22endocrine/exocrine gland phenotypeMP:000537913.4RBL2, RBL1, BRCA1, PATZ1, MXI1, CDK6
23craniofacial phenotypeMP:000538213.1RBL1, MYO6, BMP4, LAMB3, FRS2, FOXP3
24no phenotypic analysisMP:000301212.9PIK3R1, CNR1, PCNA, RB1, RBL2, RBL1
25respiratory system phenotypeMP:000538811.9SELP, NAB2, BRCA1, LPL, BID, PAM
26pigmentation phenotypeMP:000118611.8RB1, SERPINF1, BRAF, BRCA1, MYC, RAC1
27liver/biliary system phenotypeMP:000537011.7KLF6, RECK, GCLC, RBL1, VEGFA, LPL
28adipose tissue phenotypeMP:000537511.6PIK3R1, LRP1, CNR1, RB1, RBL1, SERPINE1
29other phenotypeMP:000539511.5RECK, CNR1, RARA, MSR1, JAK2, CDKN2A

Publications for genes affiliated with Prostate Carcinoma

about this section
Sources:
35PubMed
See all sources

Articles related to prostate carcinoma:

(show top 50)    (show all 949)
idTitleAuthorsYearAffiliating Genes
1SIGLEC12, a human-specific segregating (pseudo)gene, encodes a signaling molecule expressed in prostate carcinomas. (21555517)Mitra N.... Varki A.2011SIGLEC12
2Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and da mage to mitochondria. (20358476)Hilchie A.L.... Hoskin D.W.2010MAPK8, MAPK14, CASP3
3Lack of immunohistochemical detection of VEGF in prostate carcinoma. (19098681)Kamath A.... Jain D.2009VEGFA
4Characterization of ETS gene aberrations in select hi stologic variants of prostate carcinoma. (19465903)Han B.... Shah R.B.2009ERG, TMPRSS2, ETV1
5Core3 O-glycan synthase suppresses tumor formation an d metastasis of prostate carcinoma PC3 and LNCaP cells through down-regulation of alpha2beta1 integrin complex. (19395705)Lee S.H.... Fukuda M.2009ITGB1, ITGA2, B3GNT6
6Differential proteomic analysis and function study of human prostate carcinoma cells with different osseous metastatic tendency (18844116)Song D.X.... Chen C.2008HMGB1
7Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. (18240292)Mirzoeva S.... Pelling J.C.2008VEGFA, HIF1A, SETD2
8Loss of mitochondrial membrane potential is inhibited by bombesin in etoposide-induced apoptosis in PC-3 prostate carcinoma cells. (17431107)Salido M.... Vilches J.2007GRP
9Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. (16302265)Singh A.P.... Batra S.K.2006MUC1, MUC4
10The value of using an AMACR/34betaE12/p63 cocktail double staining for diagnosis of prostate carcinoma and precarcinomatous lesions (17069678)Liu Y.N.... Yang Q.H.2006RPE65, AMACR
11Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. (15712208)Yang G.... Thompson T.C.2005MYC, CAV1
12Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging. (15892807)Nargund V.... Britton K.E.2005FOLH1
13Concomitant reduction of matrix metalloproteinase-2 secretion and intracellular reactive oxygen species following anti-sense inhibition of telomerase activity in PC-3 prostate carcinoma cells. (16013445)Shariftabrizi A.... Ebrahimkhani M.R.2005MMP2, TERC
14Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. (15638997)Bouchal J.... KolA!r Z.2005TERT
15Treatment of epigallocatechin-3-gallate inhibits matrix metalloproteinases-2 and -9 via inhibition of activation of mitogen-activated protein kinases, c-jun and NF-kappaB in human prostate carcinoma DU-145 cells. (14991864)Vayalil P.K.... Katiyar S.K.2004MMP2, MAPK1, MMP9
16Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. (15316903)Chen G.... Rabbani S.A.2004AR, CTNNB1, WNT1
17The use of real-time quantitative PCR to detect circulating prostate-specific membrane antigen mRNA in patients with prostate carcinoma. (15251956)Chu D.C.... Sun C.F.2004FOLH1
18Tumor necrosis factor-related apoptosis-inducing ligand-mediated activation of mitochondria-associated nuclear factor-kappaB in prostatic carcinoma cell lines. (15498932)Guseva N.V.... Cohen M.B.2004NFKB1, RELA, TNFSF10
19Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. (15131058)Shukla S.... Gupta S.2004NFKBIA
20Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. (15048072)Huerta-Yepez S.... Bonavida B.2004BCL2L1, CASP9, TNFSF10
21Down-regulation of fragile histidine triad expression in prostate carcinoma. (12627509)Fouts R.L.... Cheng L.2003FHIT
22Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. (12673735)Chandler J.D.... Rogers S.2003SLC2A1
23Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. (12694817)Rosser C.J.... Pisters L.L.2003BCL2
24Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma. (11912448)Ni Z.... Gao A.C.2002STAT3, STAT6, STAT4
25Expression of the receptor protein-tyrosine phosphatase, PTPmu, restores E-cadherin-dependent adhesion in human prostate carcinoma cells. (11801604)Hellberg C.B.... Brady-Kalnay S.M.2002CDH1, PTPRM, GNB2L1
26Mutation analysis of the p51 gene and correlation between p53, p73, and p51 expressions in prostatic carcinoma. (11340630)Takahashi H.... Hano H.2001TP63, TP73
27The external radiotherapy with three-dimensional conf ormal boost after the neoadjuvant androgen suppression for patients with locall y advanced prostatic carcinoma. (10974471)Sumi M.... Kakizoe T.2000KLK3
28Expressions of apoptosis-associated proteins in prostate carcinoma and their clinicopathological significance (12515134)Zhang X.... Jiang Y.2000BAX
29Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. (11135218)Nishimura K.... Okuyama A.2000KLK3
30Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. (10377442)Zi X.... Agarwal R.1999KLK3
31Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter. (9445191)D'Amico A.V.... Coleman C.N.1998KLK3
32Modulation of cellular proliferation and production of prostate-specific antigen and matrix adhesion molecules in human prostate carcinoma cells by polypeptide growth factors: comparative analyses of MDA PCa2a with established cell lines. (9472097)Rajagopal S.... Chakrabarty S.1998EGF, TGFB1, KLK3
33Overexpression of manganese superoxide dismutase in DU145 human prostate carcinoma cells has multiple effects on cell phenotype. (9582091)Li N.... Zhong W.1998SOD2
34Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. (9587121)D'Amico A.V.... Richie J.P.1998KLK3
35Human prostatic carcinoma oncogene PTI-1 is expressed in human tumor cell lines and prostate carcinoma patient blood samples. (8988032)Sun Y.... Fisher P.B.1997EEF1A1
36Sphingosine induces apoptosis in androgen-independent human prostatic carcinoma DU-145 cells by suppression of bcl-X(L) gene expression. (9141489)Shirahama T.... Igarashi Y.1997BCL2, BCL2L1, BAX
37Serial lectin affinity chromatography with concavalin A and wheat germ agglutinin demonstrates altered asparagine-linked sugar-chain structures of prostatic acid phosphatase in human prostate carcinoma. (9300882)Yoshida K.I.... Kitahara S.1997ACPP
38Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. (9099957)Tjandrawinata R.R.... Hughes-Fulford M.1997PTGS2
39Which patients with prostatic carcinoma require a staging bone scan? (9126094)Kemp P.M.... Bird N.J.1997KLK3
40Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. (9218026)Ghossein R.A.... Kantoff P.W.1997KLK3
41Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis. (9815772)Uslu R.... Bonavida B.1997MYC, PTPN13, FASLG
42Clinical prognostic criteria for later diagnosis of prostate carcinoma in patients with initial isolated prostatic intraepithelial neoplasia. (8875207)Zlotta A.R.... Schulman C.C.1996KLK3
43Autocrine regulation of cell proliferation by the ins ulin-like growth factor (IGF) and IGF binding protein-3 protease system in a hu man prostate carcinoma cell line (PC-3). (7588299)Angelloz-Nicoud P.... Binoux M.1995PLAU, IGFBP3
44Prostate-specific antigen density: the role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ-confined prostate carcinoma and advanced prostate carcinoma. (8725043)IA9ikay L.... GAPA9A1A9 O.1995KLK3
45Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. (9816042)Webber M.M.... Waghray A.1995PLAU
46Phase II evaluation of coumarin (1,2-benzopyrone) in metastatic prostatic carcinoma. (1549551)Mohler J.L.... Marshall M.E.1992ACPP, KLK3
47Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. (1394216)Fong C.J.... Kozlowski J.M.1992EGFR, TGFA
48Prostate and bone fibroblasts induce human prostate c ancer growth in vivo: implications for bidirectional tumor-stromal cell interac tion in prostate carcinoma growth and metastasis. (1372662)Gleave M.E.... Chung L.W.1992C19orf10
49Differences in the leucine aminopeptidase activity in extracts from human prostatic carcinoma and benign prostatic hyperplasia. (1712242)Rackley R.R.... Resnick M.I.1991LAP3
50Clinical studies on endocrine therapy of prostatic carcinoma (1): Multivariate analyses of prognostic factors in patients with prostatic carcinoma given endocrine therapy (2191569)Kumamoto Y.... Saito Y.1990ALPP

Expression for genes affiliated with Prostate Carcinoma

about this section
Sources:
1BioGPS
See all sources
Expression patterns in normal tissues for genes affiliated with Prostate Carcinoma

Pathways for genes affiliated with Prostate Carcinoma

about this section
Sources:
20KEGG, 36QIAGEN, 10EMD Millipore, 41Thomson Reuters, 3Cell Signaling Technology
See all sources

Pathways related to prostate carcinoma according to GeneDecks:

(show top 50)    (show all 351)
idPathwayScoreTop Affiliating Genes
1Pathways in cancer2018.1PIAS3, PIK3R1, PIK3CG, NCOA4, RELA, RB1
2Focal adhesion2014.4PIK3R1, PIK3CG, VTN, BRAF, VEGFC, VCL
3Cellular Apoptosis Pathway3613.9PIK3R1, VEGFC, BMP2, BMP4, BMP6, BID
4Mitochondrial Apoptosis3613.6PIK3R1, VEGFC, BMP2, BMP4, BMP6, BID
5Cell cycle2013.4PCNA, RB1, RBL2, RBL1, MYC, CHEK2
6ERK Signaling3613.3PIK3R1, BRAF, VEGFC, MYC, BMP2, BMP4
7Activation of PKA through GPCR3613.0BRAF, VEGFC, BMP2, BMP4, BMP6, CHUK
8Glioma Invasiveness3612.9VTN, VEGFC, BMP2, BMP4, BMP6, CD44
9Integrin Pathway3612.8PIK3R1, BRAF, VCL, MYC, RAC3, RAC1
10Antioxidant Action of Vitamin-C3612.8VEGFC, MYO6, BMP2, BMP4, BMP6, RAC3
11p53 signaling pathway2012.8SERPINB5, SERPINE1, BID, CHEK2, BAX, ATM
12Activation of cAMP-Dependent PKA3612.7VEGFC, BMP2, BMP4, BAD, AXL, FLT4
13Rac1 Pathway3612.7PIK3R1, BMP4, BMP6, RAC1, JUN, ITGA2
14ERK5 Signaling3612.6VEGFC, MYC, BMP2, BMP4, BMP6, BAD
15Glioblastoma Multiforme3612.5PIK3R1, RB1, BRAF, RAC1, CDK6, CDKN1A
16MAPK Family Pathway3612.4PIK3R1, BRAF, VEGFC, BMP2, BMP4, BMP6
17G12-G13 in Cellular Signaling3612.3PIK3R1, RAC3, RAC1, CHUK, JUN, CDH2
18Endothelin-1 Signaling Pathway3612.3PIK3R1, BRAF, MYC, BMP2, BMP4, BMP6
19Colorectal Cancer Metastasis3612.2PIK3R1, BRAF, MYC, BIRC5, BCL2L1, BAX
20Development Thrombopoietin-regulated cell processes1012.2PIK3R1, BRAF, MYC, RAC1, BIRC5, BAD
21PDGF Pathway3612.0PIK3R1, RAC1, CHUK, JUN, JAK1, JAK2
22CREB Pathway3612.0PIK3R1, BMP2, BMP4, BMP6, FLT4, AREG
23Cell cycle_Cell cycle (generic schema)4112.0RB1, RBL2, RBL1, CDK6, CDK2, CDC25C
24TRKA Signaling3611.9PIK3R1, BRAF, MYC, RAC3, RAC1, BAX
25Transcription_P53 signaling pathway4111.9RELA, RB1, VEGFA, BCL2, ATM, CDKN1A
26Colorectal cancer2011.9PIK3R1, PIK3CG, BRAF, RAC3, RAC1, BAD
27Ceramide Pathway3611.9PIK3R1, BAD, JUN, FOS, FOSL2, FADD
28Angiogenesis311.8RECK, SERPINB5, VEGFC, ITGA6, ITGAV, ITGB1
29Germ Cell-Sertoli Cell Junction Dynamics3611.8VCL, RAC3, RAC1, CDH2, ITGB1, ILK
30Immune response IL-2 activation and signaling pathway1011.8PIK3R1, MYC, CHUK, LCK, JUN, JAK1
31Apoptosis and survival Role of CDK5 in neuronal death and survival1011.6BCL2, BAD, CASP9, ERBB3, CYCS, NTRK1
32PI3K Signaling in B-Lymphocyte3611.5PIK3R1, RAC1, BCL10, CHUK, FYN, JUN
33Development TGF-beta receptor signaling1011.4RELA, SERPINE1, CHUK, XIAP, FZR1, CDKN1A
34Development_TGF-beta receptor signaling4111.4RELA, SERPINE1, CHUK, XIAP, FZR1, CDKN1A
35Cell adhesion ECM remodeling1011.4VTN, SERPINE1, LAMB3, CD44, ITGB1, MMP14
36Cell adhesion_ECM remodeling4111.4VTN, SERPINE1, LAMB3, CD44, ITGB1, MMP14
37Renal cell carcinoma2011.4PIK3R1, RAC1, JUN, MET, MAPK3, ETS1
38Pancreatic cancer2011.1RAC3, CDK6, E2F2
39Apoptosis and survival Anti-apoptotic action of membrane-bound ESR11011.0MAPK9
40TREM1 Pathway3611.0PIK3R1, BRAF, BID, CHUK, BAD, BAX
41Transcription P53 signaling pathway1011.0RELA, VEGFA, CDK2, CDKN2A, MAPK8, MAPK10
42IL-6 Pathway3611.0PIAS3, PIK3R1, PIM1, BRAF, BMP2, BMP4
43TRAF Pathway3611.0PIK3R1, CHUK, UBC, JUN, FOS, IL1B
44TNF Signaling3610.9BID, CHUK, JUN, FOS, FADD, MAPK8
45Apoptotic Pathways Triggered By HIV13610.9BID, BCL2, BCL2L1, CHUK, BAX, FADD
46Apoptosis and survival Anti-apoptotic action of nuclear ESR1 and ESR21010.9RELA, MYC, BCL2, BAX, JUN, FOS
47Bladder cancer2010.8RB1, BRAF, VEGFA, VEGFC, MYC, RASSF1
48Signal transduction AKT signaling1010.8PIK3R1, GSK3B, IKBKB
49Osteoclast differentiation2010.6PIK3R1, PIK3CG, RELA, RAC1, CHUK, LCK
50Toll-like receptor signaling pathway2010.0PIK3R1, PIK3CG, RELA, RAC1, CHUK, JUN

Compounds for genes affiliated with Prostate Carcinoma

about this section
Sources:
32Novoseek , 42Tocris Bioscience, 9DrugBank, 18HMDB, 34PharmGKB
See all sources

Compounds related to prostate carcinoma according to GeneDecks:

(show top 50)    (show all 471)
idCompoundScoreTop Affiliating Genes
1atp32 20.5PIM1, RECK, VTN, RB1, RBL2, RBL1
2progesterone32 42 9 18 9 24.5PIK3R1, NCOA4, PCNA, RB1, SETD2, SERPINB5
3dexamethasone32 42 34 9 9 23.3PIK3R1, LRP1, VTN, PCNA, RB1, SELP
4paclitaxel32 34 9 9 21.7PIK3CG, PCNA, RB1, SETD2, VIM, BRAF
5heparin32 9 18 9 19.8PIK3CG, LRP1, RECK, VTN, SERPINF2, SERPINF1
6genistein32 9 18 9 19.7PIK3R1, PIK3CG, PCNA, RB1, SELP, SETD2
7forskolin32 42 9 9 19.5PIK3R1, VIM, BRAF, BMP2, BMP4, BMP6
8glucose32 16.2SETD2, SERPINF1, BRAF, VEGFC, VCL, BID
9cholesterol32 9 18 9 18.8PIK3R1, LRP1, RECK, VTN, RB1, SELP
10bromodeoxyuridine32 15.7PIK3R1, PCNA, RB1, VIM, MYC, BMP4
11resveratrol32 9 18 9 18.1PIK3CG, PCNA, RB1, BRCA1, VEGFA, VDR
12pge232 14.7VTN, SETD2, BMP2, BMP4, RAC1, SAT1
13adriamycin32 14.6RB1, VIM, BRCA1, VDR, MYC, BIRC5
14flavopiridol32 9 9 16.2PIK3CG, RB1, RBL1, VEGFA, BID, BIRC5
15docetaxel32 34 9 9 17.2SETD2, BRCA1, VEGFA, VDR, MYC, BID
16threonine32 14.0RBL2, MYO6, BMP2, LCK, FRS2, CDK6
17acetylcholine32 9 18 9 17.0CNR1, SERPINA3, VIM, LPL, VCL, BMP6
18agarose32 13.8BRCA1, MYC, BLZF1, PARP1, BCL2, BCL2L1
19gtp32 13.8PIK3R1, RECK, BRAF, RAC1, BLZF1, CHUK
20cyclosporin a32 42 14.6PIK3CG, RECK, SELP, LPL, VDR, MYC
21thapsigargin32 42 14.5PIK3CG, CNR1, PCNA, SERPINE1, BLZF1, BCL2
22gf 109203x32 42 14.2PIK3CG, VEGFA, VCL, JUN, JAK2, CDKN1A
23histidine32 13.1RARA, PAM, LGALS1, CHGA, UGT2B7, MTR
24phosphatidylserine32 9 9 14.9RECK, VIM, LPL, RAC1, BID, PARP1
253-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide32 12.8PCNA, MYC, PARP1, BCL2, BCL2L1, BAX
26erlotinib32 34 9 9 15.5VEGFA, BIRC5, CDKN1B, CDKN3, CDH1, AREG
27ibmx32 12.5LPL, BMP2, SCD, CGA, CDK2, CDKN3
28oxaliplatin32 34 9 9 15.3BRCA1, VEGFA, BIRC5, BCL2L1, MTHFR, XRCC1
29gaba32 42 13.2CNR1, VIM, CHGA, UBE3A, CDKN3, FGF8
30glycerol32 9 18 9 15.1PCNA, BRCA1, LPL, CHUK, CDK2, CD36
31daunorubicin32 9 9 14.1RELA, MYC, BIRC5, BCL2, BCL2L1, BAX
32methylcellulose32 12.0VCL, BMP2, CDH1, FGF2, IL11, IL6
33carbon32 11.9CNR1, VTN, PCNA, LPL, VDR, SCD
34inositol32 11.8LPL, CHGA, GSK3B, FGF1, GRP, MBP
35crcs32 11.7RB1, BRAF, RASSF1, BIRC5, MUC1, CEACAM5
36calyculin a32 42 9 9 14.7RB1, VIM, BCL2L1, CDK2, CDKN3, CDK1
37betacarotene32 11.7PCNA, RB1, SERPINA3, LPL, VDR, RARA
38sodium arsenite32 11.6MYC, CFLAR, JUN, FGF7, FASLG, MAPK8
39aprotinin32 9 9 13.6LRP1, SELP, SERPINF2, MMP2, MMP9, IGFBP5
40valproic acid32 34 9 18 9 15.4VCL, UGT2B7, CFLAR, CDK4, GSK3B, MCL1
4117beta-hydroxysteroid32 10.8BRCA1, UGT2B4, CGA, MKI67, AR, AKR1C1
42chloroquine32 34 9 9 13.6VTN, BRCA1, BMP6, CDH1, IL2, MAPT
43acetaminophen32 34 9 18 9 14.6PCNA, MYC, BCL2L1, UGT2B4, MMP3, ANXA5
44pioglitazone32 9 9 12.6VEGFA, LPL, RARA, JUN, MMP2, MMP7
45atorvastatin32 34 9 18 9 14.5SELP, VEGFA, LPL, BMP2, BMP6, RAC1
46pdtc32 10.5PIK3CG, GCLC, SETD2, SERPINB5, BIRC5, PARP1
47ndga32 10.0JUN, MMP3, FOS, IL1B, FASN, ANXA5
48fmlp32 9.7PIK3CG, SELP, SERPINA3, VIM, RAC1, ITGB1
49diphenyleneiodonium32 9.6SETD2, SERPINF1, VEGFA, RAC1, JUN, CDKN3
50simvastatin32 34 42 9 18 9 13.6SELP, SERPINE1, VEGFA, LPL, BMP2, BMP6

GO Terms for genes affiliated with Prostate Carcinoma

about this section
Sources:
12Gene Ontology
See all sources

Cellular components related to prostate carcinoma according to GeneDecks:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1nucleusGO:00563424.4ZNF79, PIAS3, PIM1, LRP1, KLF6, NCOA4
2cytoplasmGO:00573722.2PIAS3, PIK3CG, PIM1, LRP1, KLF6, RELA
3cytosolGO:00582918.5PIK3R1, PIK3CG, RELA, GCLC, SERPINB6, VIM
4plasma membraneGO:00588616.7PIK3R1, PIK3CG, PIM1, RECK, CNR1, SELP
5extracellular regionGO:00557616.1VTN, SERPINF2, SERPINF1, SERPINE1, SERPINA3, VEGFA
6nucleoplasmGO:00565415.5RELA, PCNA, RB1, RBL2, RBL1, BRCA1
7integral to plasma membraneGO:00588713.7LRP1, SGCE, CNR1, SELP, RAMP3, MUC1
8extracellular spaceGO:00561512.6VTN, SELP, SERPINB5, SERPINF2, SERPINF1, SERPINE1
9cell surfaceGO:00998611.4VEGFA, LPL, BMP2, RARA, RAMP3, LGALS1
10platelet alpha granule lumenGO:03109310.9SERPINF2, SERPINE1, VEGFA, VEGFC, IGF1, TMSB4X
11membrane raftGO:04512110.6BCL10, LCK, JAK2, CD36, ITGB1, GSK3B

Biological processes related to prostate carcinoma according to GeneDecks:

(show top 50)    (show all 88)
idNameGO IDScoreTop Affiliating Genes
1apoptotic processGO:00691515.0PIM1, VIM, BRCA1, BMX, RAC1, BID
2signal transductionGO:00716514.1VEGFC, LPXN, VDR, BMX, RARA, LGALS1
3cell proliferationGO:00828314.0PIM1, PCNA, SERPINF1, NAB2, BLZF1, BIN1
4mitotic cell cycleGO:00027813.9PCNA, RB1, RBL2, RBL1, BIRC5, UBC
5positive regulation of cell proliferationGO:00828413.6VEGFA, VEGFC, MYC, RARA, BIRC5, BCL2L1
6protein phosphorylationGO:00646813.4PIM1, BRAF, BMX, RARA, BIRC5, CHUK
7positive regulation of transcription, DNA-dependentGO:04589313.3KLF6, NCOA4, RELA, RB1, BRCA1, MYC
8negative regulation of cell proliferationGO:00828513.2BTG2, VDR, BMP2, BMP4, RARRES1, PAWR
9virus-host interactionGO:01904812.9PIK3R1, RELA, RB1, RBL1, VIM, BIN1
10cell adhesionGO:00715512.7VTN, SELP, LPP, LPXN, VCL, BMX
11positive regulation of gene expressionGO:01062812.6PIAS3, BRAF, VEGFA, VDR, BMP2, CDK1
12response to drugGO:04249312.6VEGFC, LPL, MYC, BGLAP, PAM, BCL2
13negative regulation of apoptotic processGO:04306612.5PIK3CG, PIM1, RELA, BTG2, SERPINE1, BRAF
14positive regulation of fibroblast proliferationGO:04814612.4MYC, JUN, CDK6, CDKN1A, CDK4, FOSL2
15protein autophosphorylationGO:04677712.4PIM1, BMX, CHEK2, ATM, FYN, JAK2
16epidermal growth factor receptor signaling pathwayGO:00717312.3PIK3R1, CHUK, UBC, BAD, CDKN1B, CDK1
17fibroblast growth factor receptor signaling pathwayGO:00854312.2PIK3R1, BRAF, CHUK, UBC, BAD, FRS2
18G1 phase of mitotic cell cycleGO:00008012.2RB1, RBL2, RBL1, UBC, CDK6, CDKN1A
19induction of apoptosis by intracellular signalsGO:00862912.1MYC, BID, BCL2, BCL2L1, BAD, BAX
20regulation of cell proliferationGO:04212712.1SERPINE1, BRCA1, BID, SAT1, XIAP, MMP7
21peptidyl-tyrosine phosphorylationGO:01810812.0FYN, JAK1, JAK2, FLT4, FGFR1, FGFR2
22innate immune responseGO:04508712.0PIK3CG, RELA, BCL10, BCL2, BCL2L1, LGALS3
23agingGO:00756811.9CNR1, SERPINF1, VDR, JUN, IL1B, FAS
24positive regulation of cell divisionGO:05178111.8VEGFA, VEGFC, FGF1, FGF2, FGF7, FGF8
25positive regulation of apoptotic processGO:04306511.8CNR1, BMP2, BMP4, BID, PAWR, BAD
26positive regulation of transcription from RNA polymerase II promoterGO:04594411.7KLF6, RELA, RB1, RBL1, SERPINF2, SERPINE1
27response to estradiol stimulusGO:03235511.6VDR, BMP4, RARA, BID, PAM, MMP9
28blood coagulationGO:00759611.5PIK3R1, PIK3CG, SELP, SERPINF2, SERPINE1, VEGFA
29nerve growth factor receptor signaling pathwayGO:04801111.5PIK3R1, RELA, BRAF, RAC1, CHUK, UBC
30platelet degranulationGO:00257611.5SELP, SERPINF2, SERPINE1, VEGFA, VEGFC, VCL
31anti-apoptosisGO:00691611.4RELA, GCLC, BRAF, BIRC5, BCL2, BCL2L1
32angiogenesisGO:00152511.4PIK3CG, SETD2, SERPINE1, VEGFA, VEGFC, SAT1
33cell-cell signalingGO:00726711.4BMP2, CGA, CGB, AR, INHA, INS
34induction of apoptosis by extracellular signalsGO:00862411.4VDR, RAC1, UBC, BAD, BAX, CFLAR
35positive regulation of MAPK cascadeGO:04341011.3CD36, CDH2, ITGB1, FLT4, AR, INS
36platelet activationGO:03016811.3PIK3R1, PIK3CG, SELP, SERPINF2, SERPINE1, VEGFA
37positive regulation of cell migrationGO:03033511.2VEGFA, BMP2, CGA, JAK2, ITGAV, ITGB1
38positive regulation of protein phosphorylationGO:00193411.1VEGFA, BMP2, BMP4, FLT4, FGF1, IL1B
39positive regulation of peptidyl-tyrosine phosphorylationGO:05073111.1VTN, VEGFA, JAK2, CD36, CD44, ITGB1
40positive regulation of protein kinase B signaling cascadeGO:05189711.1PIK3CG, AXL, INS, ILK, ANGPT1, IGFBP5
41positive regulation of ERK1 and ERK2 cascadeGO:07037411.0SERPINF2, BRAF, BMP2, BMP4, CD44, FLT4
42cellular response to mechanical stimulusGO:07126011.0BCL10, BAD, ITGB1, IL13, IL1B, FADD
43response to mechanical stimulusGO:00961211.0BTG2, BMP2, BMP4, BGLAP, JUN, MMP9
44response to hypoxiaGO:00166610.9VEGFA, BMP2, PAM, BCL2, XRCC1, ATM
45positive regulation of angiogenesisGO:04576610.8SERPINE1, VEGFA, MMP9, FGF1, FGF2, IL1B
46positive regulation of peptidyl-serine phosphorylationGO:03313810.6BRAF, VEGFA, BCL2, CD44, MIF, GSK3B
47activation of MAPK activityGO:00018710.3UBC, FRS2, CDK1, FGF10, FGF2, MET
48inflammatory responseGO:00695410.3PIK3CG, RELA, SELP, SERPINA3, BMP2, BMP6
49positive regulation of phosphatidylinositol 3-kinase cascadeGO:01406810.2SELP, UBE3A, JAK2, INS, FGFR1, ANGPT1
50positive regulation of NF-kappaB transcription factor activityGO:0510929.8RELA, BCL10, CHUK, UBC, AR, INS

Molecular functions related to prostate carcinoma according to GeneDecks:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1protein bindingGO:00551527.2TFF1, PGR, PECAM1, WNK1, WNT1, EEF1A1
2ATP bindingGO:00552415.6MAPK8, SRC, NTRK1, NTRK2, NTRK3, PPP2R4
3protein homodimerization activityGO:04280313.1NR3C1, PPP2R4, NTRK2, NTRK1, SRF, PTGS2
4transcription factor bindingGO:00813413.0MAPK9, ETS1, HMGB1, TP53, TP73, TNFRSF10A
5protein kinase bindingGO:01990112.9RELA, VIM, BCL10, BCL2L1, CHEK2, LCK
6protein heterodimerization activityGO:04698212.5NR3C1, PPP2R4, TP53, ERBB2, ERBB3, IKBKB
7identical protein bindingGO:04280212.1NFKBIA, TNF, TP73, TP63, TP53, ERBB2
8protein tyrosine kinase activityGO:00471312.1ERBB2, TEK, PTK2B, SRC, SHC1, EGFR
9enzyme bindingGO:01989911.3CSF3, SLPI, PGR, HDAC1, PIAS3, BRCA1
10growth factor activityGO:00808311.2IGF2, IGF1, F2, PDGFB, PDGFD, EGF
11cytokine activityGO:0051259.9HMGB1, TNF, TNFRSF11B, TNFSF10, TNFSF11, SPP1

Sources for Prostate Carcinoma

about this section
2CDC
11FMA
18HMDB
19ICD9CM
20KEGG
24MeSH
25MGI
27NCIt
28NDF-RT
31NINDS
32Novoseek
33OMIM
35PubMed
36QIAGEN
43UMLS
Browse MalaCards: 1-9 | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z